-
Most Recent
Search Results
240 results for cmo
Nvidia Has a Heat Problem. These Stocks Get Paid to Solve It.
Nvidia’s next chip burns power like 100 homes per rack. The stocks solving that heat problem are an overlooked trade in AI right now.
Four Stocks Prospering From the $700 Billion AI Spending Boom
The AI buildout is spreading beyond NVDA. Four infrastructure stocks are capturing a $700 billion wave most investors keep selling too soon.
M&A News Pushes Two Bank Stocks to New Highs
Financial stocks are bouncing back, with Parkvale Financial and Southern Union Co. up against new highs. Tech stocks, on the other hand, are struggling.
The Inspector’s Eye: How We Read Past the Sticker Price on AI’s Biggest Movers
Luke Lango and the team explain EBIT vs. EBITDA and break down buy zones on optics stocks, BWXT, Bloom Energy, and Micron in this week’s…
KFC Pickled Fried Chicken Is Now a Thing
KFC has now rolled out pickled fried chicken in an attempt to compete with Chick-fil-A, which has a similar sandwich, which has proven to be…
Netflix Earnings: NFLX Stock Dips on Q1 EPS Beat, Weak Q2 Guidance
Netflix earnings were unveiled today, with the company topping expectations across the board. A light guidance caused NFLX stock to slide.
20 Stocks Headed for a Meltdown
These stocks are likely to break down before the overall market does.
Angie’s List Inc (ANGI) Stock Skyrockets on Buyout News
Angie’s List (ANGI) stock was flying high on Tuesday following news of a buyout offer as it plans to merge with HomeAdvisor.
Naming of New Papa John’s CEO Sends PZZA Stock Higher
There’s a new Papa John’s CEO leading the company and the news of Rob Lynch joining has PZZA stock on its way up Thursday.
Dunkin’ Donuts Says Goodbye to Artificial Dyes
Dunkin’ Donuts has announced that it is no longer using artificial dyes in its donuts that are sold in the United States.
Get a Dozen Krispy Kreme Donuts for 80 Cents This Friday!
Krispy Kreme Doughnuts has a special promotional offer for an order of a dozen of its Krispy Kreme donuts on Friday, July 14, 2017.
Why Amicus Therapeutics, Inc. (FOLD) Stock Is Soaring Today
Amicus Therapeutics (FOLD) stock was flying high today on positive news from the U.S. Food and Drug Administration for migalastat.
15 Highest Paying Dividend Plays
You’ll find that the stocks below are sporting some pretty nice dividends, but don’t just dive into one of the stocks listed below without doing…
Is Matterport Ready for the Scrap Heap?
Newly hired Chief Marketing Officer Tom Klein will have to work his magic if Matterport and MTTR stock are to rise from the scrap heap.
Shopify News: SHOP Stock Shoots 10% Higher on Deal With Chipotle
Shopify (SHOP) is in the news Wednesday following the announcement of a deal with Chipotle (CMG) to set up a virtual farmer’s market.
The AI Winning the Most Money Isn’t the One You’re Thinking Of
On Tuesday, we looked at how AI is making the oil and gas industry more efficient with Joe Austin. Today, we’re looking at another place…
National Avocado Day 2019: Get Your Free Chipotle Guacamole Today!
National Avocado Day 2019 is here and that means customers that stop by Chipotle (CMG) can get free guacamole when they order an entree.
APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News
Aptorum (APM) stock is on the rise Wednesday after announcing approval to move forward with a clinical trial of its staph infection drug.
Target to Launch 4 New Private-Label Brands
Target (TGT) is planning to introduce four new private label brands later this year in an effort to bring customers back to its stores.
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial.
Oh Deer! Arby’s Venison Sandwich Returns Oct. 21
Arby’s deer-filled Venison Sandwich will be making a return to stores nationwide later this month to kick off hunting season.
Why Cara Therapeutics Inc (CARA) Stock Is Plunging Today
Cara Therapeutics (CARA) stock was hit hard on Friday following poor results in its Phase 2b trial of osteoarthritis oral drug CR845.
5 – 10 of 240 results
